You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: R

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery

    SBC: Cell Microsystems, Inc.            Topic: 200

    DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer s therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD occurs in one out of eight Americans of age and affects of the elderly over Current FDA approved drugs provide short term symptomatic relief of AD There is a pressing need to discover new disease modifying medications AD is multifactorial in origin and progression A drug attenuating several underlying factors is a p ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 106

    Abstract Neurological conditions such as multiple sclerosis Parkinson s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary voiding of urine and require intermittent bladder catheterization for voiding Catheter use is associated with increased incidence of health problems predominately repeated urinary tract infections sepsis ureth ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF remains the most commonly occurring cardiac arrhythmia It is associated with a lower quality of life and a higher rate of morbidity andamp mortality primarily due to poor hemodynamics and often stroke One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequ ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter BioSphincter to Treat Fecal Incontinence

    SBC: CELLF-BIO, LLC            Topic: 300

    DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: 100

    DESCRIPTION provided by applicant While HIV AIDS can be managed with antiretroviral drugs these agents do not clear the virus and require life long administration Recently we discovered a completely new class of compounds that interfere with the HIV virulence factor called Nef This viral protein is critical to HIV replication in vivo immune escape of HIV infected cells and AIDS progre ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re

    SBC: Apogee Biotechnology Corporation            Topic: 102

    DESCRIPTION provided by applicant Diffuse large B cell lymphoma DLBCL represents one of the most common variants of Non Hodgkinandapos s lymphoma NHL and oncogenic herpesviruses EBV and KSHV are the etiologic agents for the majority of these tumors in patients over or those infected with the human immunodeficiency virus HIV Despite modest improvements in outcomes for patients rece ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government